Tag: GLP-1
In brief: Abbott’s spin-off, ABM’s raise, F&P’s cyber incident, GLP-1’s OSA impact
October 23, 2026HME News Staff
ABBOTT PARK, Ill. – Abbott plans to separate its nutrition business into an independent, publicly traded company with approximately $8.5 billion in annual sales.
"As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market," said Robert B. Ford, chairman and CEO, Abbott. "Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition,...
GLP-1s show promise as complement to CPAP for sleep apnea, researchers say
September 29, 2026HME News Staff
YARMOUTH, Maine – GLP-1 receptor agonists like tirzepatide are best used to treat obesity-related obstructive sleep apnea (OSA) alongside CPAP, according to a new abstract in JAMA Otolaryngology – Head & Neck Surgery. Researchers found that multiple studies showed the medications consistently reduced apnea-hypopnea index (AHI) scores, with the SURMOUNT-OSA trials reporting reductions of 20 to 24 events per hour and disease remission in 42% to 50% of patients. The drugs appear to work...
In brief: CGMs are essential & effective, GLP-1s & CPAP are better together
September 25, 2026HME News Staff
MILAN – A majority of health care providers (HCPs) recognize continuous glucose monitoring (CGM) as essential to Type 2 diabetes management, according to a new report published by Dexcom ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan Sept. 28-Oct. 2.
Eighty-nine percent of HCPs believe CGM helps them assess treatment adherence between appointments, and more than half of current CGM users report they have followed their treatment plan...
Lilly’s investigational GLP-1 reduces AHI by up to 36 events per hour in OSA patients
June 8, 2026HME News Staff
INDIANAPOLIS – Eli Lilly, the maker of Zepbound and Foundayo, has announced positive results from Phase 3 trials of retatrutide, an investigational GLP-1, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and Type 2 diabetes – common obesity-related conditions.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,"...
As GLP-1 use rises, so does awareness of sleep apnea, says Blackstone CEO
February 6, 2026Theresa Flaherty
TAMPA, Fla. – With Novo Nordisk’s pill version of Wegovy now widely available, GLP-1 drugs are poised for even greater adoption. That surge is fueling awareness of the link between obesity and sleep apnea – and driving demand for sleep testing, says Vick Tipnes, CEO and founder of Blackstone Medical Services.
Fortunately, people recognize there's a connection between health concerns like being overweight and the risk of having...
Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Healthcare Conference
January 16, 2026Liz Beaulieu, Editor
SAN FRANCISCO – Resmed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Smart Comfort, will help improve both short- and long-term compliance with therapy.
Resmed announced in late 2025 that the U.S. Food and Drug Administration (FDA) had cleared Smart Comfort. The technology will launch in a limited beta in early 2026 for new...
Do weight-loss drugs reduce need for CPAP? Modestly, according to new research
December 30, 2025HME News Staff
YARMOUTH, Maine – Popular weight-loss drugs, especially tirzepatide, are linked to modestly lower CPAP initiation among adults with Type 2 diabetes and obstructive sleep apnea (OSA), according to a research letter in the Journal of the American Medical Association (JAMA). Researchers found a stronger link between the drugs and reduced hospitalization and mortality. “These findings align with recent randomized clinical trials showing...
In brief: CMS lifts claims hold, Eli Lilly drafts Shaq, Menlo Ventures surveys AI adoption
October 29, 2025HME News Staff
WASHINGTON – CMS has instructed all Medicare Administrative Contractors (MACs) to lift the claims hold and process claims with dates of service Oct. 1, 2025, and later for certain services impacted by select expired Medicare legislative payment provisions passed under the Full-Year Continuing Appropriations and Extensions Act of 2025.
This includes claims paid under the:
Medicare Physician Fee Schedule
Ground ambulance transport
Federally Qualified Health...
Eli Lilly, O’Neal 'break through stigma’ of obstructive sleep apnea
October 28, 2025HME News Staff
INDIANAPOLIS – Eli Lilly has a new partnership with NBA Hall of Famer and cultural icon Shaquille O’Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA).
The campaign aims to educate the public about symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity, the company says.
"Moderate-to-severe...
Resmed advocates for fair reimbursement, stands behind CPAP
August 1, 2025Liz Beaulieu, Editor
SAN DIEGO – Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The resurgence of Medicare’s competitive bidding program and the development of a new pill to treat obstructive sleep apnea (OSA).
Questioning bid program, savings
Farrell said Resmed is discussing competitive bidding directly with leadership at Health and Human Services and CMS, and working with AAHomecare and AdvaMed to respond to the proposed...